Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3694 - Detection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): circulating tumour (ct) DNA analysis across 3 platforms

Date

09 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Targeted Therapy;  Non-Small Cell Lung Cancer

Presenters

Caicun Zhou

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

C. Zhou1, M. Wang2, Y. Cheng3, Y. Chen4, X. Ye5, Y. Sun5, X. Huang6, S. Patel6, Y. Chen5, Y. Wu7

Author affiliations

  • 1 Shanghai Pulmonary Hospital, Tongji University, 200433 - Shanghai/CN
  • 2 Department Of Respiratory Medicine, Peking Union Medical College Hospital, 100730 - Beijing/CN
  • 3 Department Of Oncology, Jilin Cancer Hospital, Jilin/CN
  • 4 Cancer Centre Of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan/CN
  • 5 China Development Unit, AstraZeneca, Shanghai/CN
  • 6 Biostatistics And Informatics, AstraZeneca, Cambridge/GB
  • 7 Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou/CN
More

Resources

Abstract 3694

Background

Osimertinib is an oral, potent, CNS active, irreversible EGFR-TKI approved to treat pts with T790M-positive NSCLC. Non-invasive methods to confirm presence of T790M are needed to identify pts who could benefit.

Methods

AURA17 (NCT02442349) is a Phase II, single arm study investigating the safety and efficacy of osimertinib 80 mg once daily in an Asia-Pacific pt population with T790M positive advanced NSCLC, who had disease progression following EGFR-TKI therapy. Tumour tissue T790M status was centrally confirmed by cobas® EGFR Mutation Test (Roche Molecular Systems). Where possible, matched plasma ctDNA samples collected at screening were analysed for EGFR mutations using 3 tests: cobas® EGFR Mutation Test v2.0 (cobas plasma), AmoyDx SuperARMS EGFR T790M Mutation Detection Kit (SuperARMS) and droplet digital PCR (ddPCR; in-house research assay).

Results

Table summarises concordance data.Table:

1331P Sensitivity and specificity of plasma tests using cobas tissue test as the reference

% (95% CI)cobas plasma (n = 240)SuperARMS (n = 249)ddPCR (n = 249)
T790MPPA42 (34, 50)49 (41, 57)56 (48, 64)
NPA83 (72, 91)78 (67, 86)73 (62, 83)
L858RPPA65 (54, 75)NA*62 (51, 72)
NPA100 (98, 100)NA*99 (96, 100)
Exon 19 deletionsPPA86 (80, 92)NA*66 (58, 74)
NPA97 (91, 99)NA*98 (93, 100)

NPA, negative percent agreement (specificity); PPA, positive percent agreement (sensitivity); *SuperARMS used solely for detection of T790M Number of patients tested with cobas tissue test: 277 In the evaluable for response (EFR; 4 March 2016 data cut-off) set, pts with T790M-positive status by both tumour and plasma analysis had confirmed objective response rates (ORR) with osimertinib (RECIST 1.1 by blinded independent central review) of 56% (95% CI 43, 69; 36/64 pts) using cobas plasma, 64% (52, 74; 49/77 pts) using SuperARMS, and 56% (45, 67; 49/87 pts) using ddPCR. ORR in the overall EFR tumour T790M-positive population was 60% (52, 68; 100/166 pts).

Conclusions

Using cobas tissue test as the reference, sensitivity for plasma T790M detection slightly increased with superARMS and ddPCR compared to cobas plasma test. Conversely, specificity slightly decreased. In pts with tumour T790M positive status, ORR with osimertinib was consistent across plasma tests, and with the overall tumour T790M-positive population. Biopsy is recommended for pts with a plasma T790M-negative test result, where feasible.

Clinical trial identification

NCT02442349

Legal entity responsible for the study

AstraZeneca

Funding

AstraZeneca

Disclosure

C. Zhou: Lecture honorarium: Eli Lily, AstraZeneca, Roche, Pfizer, Sanofi, Boehringer Iingelheim, Henrui Advisory Board: Roche, Boehringer Ingelheim, AstraZeneca. Y. Cheng: No financial interest in products or processes involved in our research. X. Ye, Y. Sun, X. Huang: Employee of AstraZeneca. S. Patel: Employee of, and shareholder in, AstraZeneca. Y-L. Wu: Speaker fees from AstraZeneca, Roche, Eli Lilly, Sanofi, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.